opgen
announces
award
german
government
grant
funding
subsidiary
curetis
collaborators
project
look
rapid
molecular
diagnostics
travel
related
enteric
diseases
small
animals
veterinary
applications
developed
unyvero
rq
platform
curetis
collaborate
carpegen
munich
gaithersburg
md
holzgerlingen
germany
globe
newswire
opgen
nasdaq
opgn
opgen
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
announced
today
award
german
federal
government
grant
subsidiary
curetis
gmbh
collaborators
carpegen
gmbh
muenster
germany
clinic
small
animal
internal
medicine
lmu
university
munich
germany
project
originally
initiated
via
vetdx
network
berlin
brandenburg
set
receive
funding
zentrales
innovationsprogramm
mittelstand
central
innovation
program
medium
sized
growth
companies
collaboration
academic
institutions
project
focus
travel
related
enteric
diseases
small
animals
area
growing
concern
increasing
incidence
rates
several
diseases
caused
potential
zoonotic
pathogens
could
also
passed
humans
looking
veterinary
applications
one
might
also
help
prevent
human
diseases
future
currently
comparable
rapid
automated
sample
answer
molecular
diagnostic
system
would
target
diseases
collaboration
partners
believe
needed
successfully
address
unmet
clinical
need
primary
project
objective
develop
molecular
diagnostics
platform
infectious
diseases
small
animals
project
starts
december
grant
project
volume
half
million
euros
curetis
expects
receive
eur
funding
time
specifically
project
targeting
travel
related
enteric
diseases
small
animals
parasitic
diseases
viral
infectious
diseases
curetis
contribution
focusing
development
integration
sample
preparation
assays
onto
unyvero
rq
platform
well
integration
dried
reagents
diagnostic
test
cartridges
run
system
collaboration
partner
carpegen
focusing
development
dried
reagents
joint
sample
preparation
assay
development
efforts
together
team
curetis
academic
partner
lmu
responsible
sample
acquisition
prototype
validation
well
providing
reference
strains
excited
collaborate
carpegen
lmu
project
help
expand
use
unyvero
platform
development
developing
rapid
veterinary
diagnostics
tests
automated
platform
potentially
open
future
commercial
partnering
opportunities
said
oliver
schacht
phd
ceo
opgen
really
looking
forward
participating
exciting
project
first
project
carpegen
targeting
veterinary
market
said
antje
roetger
phd
ceo
carpegen
addition
pleased
ongoing
opportunity
work
project
involving
opgen
unyvero
rq
platform
since
first
prototype
promising
platform
developed
within
r
project
led
happy
opportunity
contribute
new
system
veterinary
diagnostics
annual
case
load
patients
first
opinion
referral
clinic
experience
every
day
need
accurate
fast
diagnosis
infectious
diseases
consider
obligation
find
solutions
patients
pet
owners
veterinarians
working
private
practices
developing
economical
laboratory
tests
collaboration
innovative
industry
said
karin
weber
head
laboratory
clinic
small
animal
internal
medicine
lmu
munich
clinic
small
animal
internal
medicine
part
lmu
munich
leading
academic
institution
field
veterinary
internal
medicine
cats
dogs
strives
actively
participate
development
sustainable
diagnostic
systems
small
animal
medicine
professional
expertise
ensure
products
align
market
needs
university
research
group
would
like
contribute
significantly
progress
systems
veterinary
medicine
university
veterinary
clinic
would
like
improve
diagnostic
possibilities
small
animal
medicine
benefit
animal
patients
carpegen
carpegen
muenster
germany
provider
molecular
diagnostics
focus
developing
pcr
assays
systems
diagnosis
specific
infections
detection
genetic
biomarkers
carpegen
developed
perio
diagnostics
powerful
pcr
based
system
sets
new
standards
dental
diagnostics
main
objective
carpegen
research
program
develop
poc
pcr
systems
diverse
applications
medicine
well
food
beverage
environmental
analytics
since
carpegen
offers
sensitive
specific
pcr
diagnostics
detection
coronavirus
disease
opgen
opgen
gaithersburg
md
usa
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
along
subsidiaries
curetis
gmbh
ares
genetics
gmbh
developing
commercializing
molecular
microbiology
solutions
helping
guide
clinicians
rapid
actionable
information
life
threatening
infections
improve
patient
outcomes
decrease
spread
infections
caused
microorganisms
mdros
opgen
product
portfolio
includes
unyvero
acuitas
amr
gene
panel
lighthouse
ares
technology
platform
including
aresdb
using
ngs
technology
bioinformatics
solutions
antibiotic
response
prediction
information
please
visit
statements
press
release
includes
statements
regarding
award
grant
german
government
curetis
gmbh
development
efforts
veterinary
applications
unyvero
rq
platform
statements
statements
regarding
opgen
products
commercialization
launch
future
plans
goals
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
intended
qualify
safe
harbor
liability
established
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
often
difficult
predict
beyond
control
may
cause
results
differ
materially
expectations
factors
could
cause
results
differ
materially
described
include
limited
ability
successfully
timely
develop
seek
obtain
regulatory
clearance
commercialize
product
services
offerings
rate
adoption
products
services
hospitals
healthcare
providers
success
commercialization
efforts
impact
company
operations
financial
results
commercialization
efforts
well
capital
markets
general
economic
conditions
realization
expected
benefits
business
combination
transaction
curetis
gmbh
effect
business
existing
new
regulatory
requirements
economic
competitive
factors
discussion
significant
risks
uncertainties
associated
opgen
business
please
review
filings
securities
exchange
commission
cautioned
place
undue
reliance
statements
based
expectations
date
press
release
speak
date
press
release
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
opgen
contact
oliver
schacht
ceo
investorrelations
press
contact
matthew
bretzius
fischtank
marketing
pr
matt
investor
contact
megan
paul
edison
group
mpaul
